Sugi Predict

Sugi Predict / Compounds / SCHEMBL8912847

SCHEMBL8912847

SCHEMBL8912847

Cc1ccc(C2=CCN(C(=O)OC(C)(C)C)CC2)cc1

nearest known ligand 0.63

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ NAMPT P43490 1/20 0.63
▸ PDK4 Q16654 1/20 0.58
▸ GRM1 Q13255 11/20 0.55
▸ GRM5 P41594 11/20 0.55
▸ KIT P10721 1/20 0.50
▸ HTR6 P50406 1/20 0.50
▸ GPR119 Q8TDV5 1/20 0.50
▸ CDK7 P50613 1/20 0.50
▸ CDK13 Q14004 1/20 0.50
▸ CDK12 Q9NYV4 1/20 0.50
▸ TNK2 Q07912 1/20 0.49
▸ CYP11B2 P19099 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL904049 0.90 NAMPT (0.61) NAMPTPDK4GRM1GRM5HTR6
SCHEMBL578028 0.89 NAMPT (0.60) NAMPTPDK4GRM1GRM5HTR6
SCHEMBL652961 0.89 NAMPT (0.60) NAMPTPDK4GRM1GRM5HTR6
SCHEMBL19989639 0.89 NAMPT (0.67) NAMPTPDK4GRM1GRM5HTR6
SCHEMBL18619842 0.89 NAMPT (0.60) NAMPTPDK4GRM1GRM5HTR6
SCHEMBL2908091 0.89 NAMPT (0.60) NAMPTPDK4GRM1GRM5HTR6
SCHEMBL29227506 0.89 NAMPT (0.60) NAMPTPDK4GRM1GRM5HTR6
SCHEMBL2594283 0.89 GRM1 (0.65) NAMPTPDK4GRM1GRM5KIT
SCHEMBL18619845 0.89 NAMPT (0.60) NAMPTPDK4GRM1GRM5HTR6
SCHEMBL2239831 0.89 NAMPT (0.66) NAMPTPDK4GRM1GRM5HTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12479816-B2 20-HETE formation inhibitors University of Pittsburgh—of the Commonwealth System of Higher Education (US) 2025-11-25 — — US disclosed
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS, SAN DIEGO 2023-11-23 — — US disclosed
US-20220144797-A1 20-HETE FORMATION INHIBITORS UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2022-05-12 — — US disclosed
US-20220144797-A1 20-HETE FORMATION INHIBITORS UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2022-05-12 — — US disclosed
WO-2022073469-A1 COMPOUNDS AND METHODS OF TREATING CANCERS CULLGEN (SHANGHAI) , INC. (CN) 2022-04-14 — — WO disclosed
WO-2020163689-A1 20-HETE FORMATION INHIBITORS UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2020-08-13 — — WO disclosed
WO-2020163689-A1 20-HETE FORMATION INHIBITORS UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2020-08-13 — — WO disclosed
EP-2870150-B1 HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS 3 V BIOSCIENCES INC (US) 2019-06-19 — — EP disclosed
US-10301299-B2 Glycosidase inhibitors MERCK PATENT GMBH (DE) 2019-05-28 — — US disclosed
US-10301299-B2 Glycosidase inhibitors MERCK PATENT GMBH (DE) 2019-05-28 — — US disclosed
EP-2970272-A1 GLYCOSIDASE INHIBITORS Merck Patent GmbH (DE) 2016-01-20 — — EP disclosed
WO-2014159234-A1 GLYCOSIDASE INHIBITORS MERCK PATENT GMBH (DE) 2014-10-02 — — WO disclosed
WO-2014159234-A1 GLYCOSIDASE INHIBITORS MERCK PATENT GMBH (DE) 2014-10-02 — — WO disclosed
WO-2013157022-A1 SUBSTITUTED HETERO-BICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF ADVINUS THERAPEUTICS LIMITED (IN) 2013-10-24 — — WO disclosed
US-20120238750-A1 AROMATIC COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. 2012-09-20 — — US disclosed
US-8236826-B2 Diarylether derivatives as antitumor agents OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-08-07 — — US disclosed
US-8188277-B2 Aromatic compounds for suppressing the generation of collagen OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-05-29 — — US disclosed
US-20100004438-A1 DIARYLETHER DERIVATIVES AS ANTITUMOR AGENTS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2010-01-07 — — US disclosed
US-20070270422-A1 Aromatic Compounds OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-11-22 — — US disclosed
US-20070270422-A1 Aromatic Compounds OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-11-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CFTR, SCNN1G, SCNN1B NAMPT 1836/4885PDK4 4019/4885GRM1 2638/4885
US-20120238750-A1 AROMATIC COMPOUND CBR1, CBR3, CYP1A1 NAMPT 4214/4885PDK4 1568/4885GRM1 627/4885
US-10301299-B2 Glycosidase inhibitors GAA, BACE1, GBA3 NAMPT 719/4885PDK4 2751/4885GRM1 451/4885
US-20220144797-A1 20-HETE FORMATION INHIBITORS CYP4A22, ALOX5, ALOX15 NAMPT 1444/4885PDK4 1189/4885GRM1 2182/4885
US-12479816-B2 20-HETE formation inhibitors CYP4A22, ALOX5, ALOX15 NAMPT 1444/4885PDK4 1189/4885GRM1 2182/4885
US-20100004438-A1 DIARYLETHER DERIVATIVES AS ANTITUMOR AGENTS ROS1, CBR1, CBR3 NAMPT 3393/4885PDK4 1574/4885GRM1 1069/4885
US-20070270422-A1 Aromatic Compounds COL1A1, COL2A1, COL14A1 NAMPT 4432/4885PDK4 2158/4885GRM1 2733/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.